Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies
Collecte de données
Étude thérapeutique
Résumé
Date de début de l'étude : 1 avril 2003
Date à laquelle le premier participant a commencé l'étude.OBJECTIVES: Primary * Determine the maximum tolerated dose of BCX-1777 in patients with refractory T-cell or non-T-cell malignancies. * Determine the safety and dose-limiting toxicity of this drug in these patients. Secondary * Determine the pharmacokinetics of single oral and single and multiple IV doses of this drug in these patients. * Determine the oral bioavailability of this drug in these patients. * Determine, preliminarily, the antitumor activity of this drug in these patients. OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study. * Courses 1 and 2: Patients receive oral BCX-1777 on days 1 and 15\* and BCX-1777 IV over 30 minutes on days 8\* and 22\*. * Course 3: Beginning approximately 6 days\* after the completion of courses 1 and 2, patients receive BCX-1777 IV over 30 minutes once daily on days 1-5 and 8-12 (total of 10 doses). NOTE: \*+/- 1 day Patients with stable disease or better and no dose-limiting toxicity (DLT) may receive an additional 10-dose treatment course (as in course 3) after a 10- to 16-day drug-free interval. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Patients are followed at 14 and 30 days. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Critères
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Hematologic malignancy that is refractory to at least 1 prior curative treatment * Non-hematologic tumor that is refractory to at least 2 prior therapies, with or without measurable disease, including the following: * Gastrointestinal adenocarcinoma of 1 of the following sites: * Pancreatic * Biliary * Gastric * Colorectal * Esophageal * Melanoma * Ovarian cancer * Astrocytoma brain tumor * Not immediately eligible for any other treatment that would be potentially curative or life-prolonging, in the opinion of the investigator * Patients who may be candidates for future bone marrow transplantation are eligible * No brain metastases (other than astrocytomas) * No clinically significant pleural effusion * No complete tumor obstruction (e.g., bronchus, ureter, or bowel) PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 OR * Karnofsky 50-100% Life expectancy * Not specified Hematopoietic * WBC at least 3,500/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count greater than 50,000/mm\^3 * Hematocrit stable without the need for transfusion (epoetin alfa support allowed) Hepatic * Bilirubin less than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome) * SGOT and SGPT less than 2 times ULN * No active hepatitis B or C Renal * Creatinine clearance at least 50 mL/min Cardiovascular * No American Heart Association class III or IV cardiac disease Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No active systemic infection requiring IV antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Concurrent corticosteroids allowed provided the patient is on a stable regimen Radiotherapy * Not specified Surgery * Not specified Other * Recovered from prior therapy * No grade 2-4 toxicity * More than 3 weeks since prior antineoplastic and/or investigational therapy * No other concurrent systemic antineoplastic or investigational therapy
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site